A composite assay for HER2-positive early-stage breast cancer management
Ente Finanziatore: Piano Nazionale di Ripresa E Resilienza (PNRR) Missione 6 - Componente 2 - Investimento 2.1 Valorizzazione e Potenziamento Della Ricerca Biomedica del SSN
Principal Investigator: Dott. Verderio Paolo
Co Principal Investigator: PhD Di Cosimo Serena
Data di inizio:
Data di fine:
Struttura Principale: Bioinformatica e Biostatistica
This PNRR-funded project involves the National Cancer Institute in Milan, in collaboration with the “Di Summa-Perrino” Hospital in Brindisi and the National Cancer Institute IRCCS Fondazione Pascale in Naples.
The project tackles the challenge of identifying which patients are likely to benefit from anti-HER2 treatments. Its goal is to develop a prognostic classifier for HER2-positive breast cancer, a user-friendly tool capable of predicting disease outcomes and the likelihood of individual therapeutic success, based on both clinical and biological data. This approach could pave the way for more personalized treatment plans and the development of innovative strategies, with a particular focus on those patients most likely to benefit.
Principal Investigator Dr. Verderio Paolo
Co Principal Investigator PhD Di Cosimo Serena
Struttura Principale: Bioinformatics and Biostatistics Unit
Simple Structure
Anatomia patologica 2
Struttura complessa
Breast Cancer Radiotherapy Unit
Clinical Area, Simple Structure
Last update: 27/08/2025